Search
Safusidenib
go.drugbank.com/drugs/DB18745InvestigationalSynonyms: DS-1001 free acid, (2E)-3-[1-[[5-(1-Fluoro-1-methylethyl)-3-(2,4,6-trichlorophenyl)-4-isoxazolyl]carbonyl]-3-methyl-1H-indol-4-yl]-2-propenoic acidPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalIn clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L940] … Pibrentasvir is available as an oral combination therapy with [DB13879] under the brand name Mavyret.
Mixtures: MAVİRET 100 MG/40 MG FİLM KAPLI TABLET, 84 ADET, MAVIRET® 100/40 MG TABLETAS RECUBIERTASCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP1A2 InhibitorsLusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalx 10^9/L were administered lusutrombopag orally [L4166]. … In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Piperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.
Mixtures: KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 120 ML, KWELL-P %0,3 + %3 MEDİKAL ŞAMPUAN, 60 MLCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InhibitorsAbametapir
go.drugbank.com/drugs/DB11932Approved[A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsrsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Benzoic acid
go.drugbank.com/drugs/DB03793ApprovedInvestigationalA fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid. … As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.
Mixtures: ARTU 100 ML SURUP, GAYABEKSIN 150 ML SURUPNaldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.